Notice2024-10198
Prospective Grant of an Exclusive Patent License: Antibody-Drug Conjugates (ADCs) for Targeting CD56-Positive Tumors
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
May 10, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this Notice to McSAF Inside Oncology SAS ("McSAF Inside Oncology") located in Tours, France.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 92 (Friday, May 10, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 92 (Friday, May 10, 2024)]
[Notices]
[Page 40495]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-10198]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Antibody-Drug
Conjugates (ADCs) for Targeting CD56-Positive Tumors
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute, an institute of the National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an Exclusive Patent License to practice the
inventions embodied in the Patents and Patent Applications listed in
the SUPPLEMENTARY INFORMATION section of this Notice to McSAF Inside
Oncology SAS (``McSAF Inside Oncology'') located in Tours, France.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before May 28, 2024 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated Exclusive Patent License
should be directed to: Rose Freel, Ph.D., Unit Supervisor, NCI
Technology Transfer Center, Telephone: (301) 624-1257; Email:
<a href="/cdn-cgi/l/email-protection#b0c2dfc3d59ed6c2d5d5dcf0ded9d89ed7dfc6"><span class="__cf_email__" data-cfemail="760419051358100413131a36181f1e58111900">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
Intellectual Property
1. United States Provisional Patent Application No. 62/199,707
filed July 31, 2015, entitled ``Antibody-drug conjugates for targeting
CD56-positive tumors'' [HHS Reference No. E-221-2015-0-US-01];
2. International Patent Application No. PCT/US2016/044777 filed
July 29, 2016, entitled ``Antibody-drug conjugates for targeting CD56-
positive tumors'' [HHS Reference No. E-221-2015-0-PCT-02]; and
3. United States Patent No. 10,548,987 issued February 02, 2020
(corresponding to United States Patent Application No. 15/747,620 filed
January 25, 2018), entitled ``Antibody-drug conjugates for targeting
CD56-positive tumors'' [HHS Reference No. E-221-2015-0-US-03].
The patent rights in these inventions have been assigned and/or
exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be worldwide, and
the field of use may be limited to the following:
``The use, development, and commercialization of an antibody-drug
conjugate (ADC) for the treatment of Merkel cell carcinoma, wherein the
ADC utilizes any technology for attachment of the cytotoxic payload and
has:
(1) The CDR sequences of the m906 antibody; and
(2) a cytotoxic payload.''
and
``The use, development, and commercialization of an antibody-drug
conjugate (ADC) for the treatment of CD56-positive cancers except
glioblastoma, wherein the ADC:
(1) has the CDR sequences of the m906 antibody;
(2) has a cytotoxic payload; and
(3) utilizes solely McSAF Inside Oncology's proprietary or
exclusively in-licensed bioconjugation technologies for attachment of
the linker-payload(s) to the m906 antibody.
The E-221-2015 patent family is directed to ADCs utilizing the
CD56-specific monoclonal antibody known as m906 and conjugated to a
drug. The technology is intended to be used as a therapeutic for CD56-
positive cancers such as neuroblastoma, multiple myeloma, ovarian
cancer, acute myeloid leukemia, and small cell lung cancer. The
exclusive field of use which may be granted to McSAF Inside Oncology
applies to only ADCs which either (1) treat Merkel Cell Carcinoma; or
(2) use McSAF Inside Oncology's proprietary bioconjugation platform for
attachment of the antibody to the linker-payload. Accordingly, the
proposed scope of rights which may be conveyed under the license covers
only a portion of the total scope of the E-221-2015 patent family and
only a subset of the possible ADCs that incorporate the m906 antibody
as well as the possible therapeutic applications of the ADCs.
This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published Notice, the National
Cancer Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially and may be made
publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information from these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: May 6, 2024.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2024-10198 Filed 5-9-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on May 10, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.